GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Inventories, Finished Goods

APLM (Apollomics) Inventories, Finished Goods : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Inventories, Finished Goods?

Apollomics Inventories, Finished Goods Historical Data

The historical data trend for Apollomics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Inventories, Finished Goods Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
- - - -

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventories, Finished Goods Get a 7-Day Free Trial - - - - -

Apollomics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Apollomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Inventories, Finished Goods
Comparable Companies
ATHA STTK ACXP CARA TLSA ORMP IMMX CCCC GTHX GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
APLMW:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.